SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-534377"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-534377" > Identifying therape...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00007188naa a2200697 4500
001oai:DiVA.org:uu-534377
003SwePub
008240704s2024 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:238684708
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5343772 URI
0247 a https://doi.org/10.1038/s41467-024-46834-32 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:2386847082 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Smith-Byrne, Karlu Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.4 aut
2451 0a Identifying therapeutic targets for cancer among 2074 circulating proteins and risk of nine cancers
264 1b Springer Nature,c 2024
338 a electronic2 rdacarrier
520 a Circulating proteins can reveal key pathways to cancer and identify therapeutic targets for cancer prevention. We investigate 2,074 circulating proteins and risk of nine common cancers (bladder, breast, endometrium, head and neck, lung, ovary, pancreas, kidney, and malignant non-melanoma) using cis protein Mendelian randomisation and colocalization. We conduct additional analyses to identify adverse side-effects of altering risk proteins and map cancer risk proteins to drug targets. Here we find 40 proteins associated with common cancers, such as PLAUR and risk of breast cancer [odds ratio per standard deviation increment: 2.27, 1.88-2.74], and with high-mortality cancers, such as CTRB1 and pancreatic cancer [0.79, 0.73-0.85]. We also identify potential adverse effects of protein-altering interventions to reduce cancer risk, such as hypertension. Additionally, we report 18 proteins associated with cancer risk that map to existing drugs and 15 that are not currently under clinical investigation. In sum, we identify protein-cancer links that improve our understanding of cancer aetiology. We also demonstrate that the wider consequence of any protein-altering intervention on well-being and morbidity is required to interpret any utility of proteins as potential future targets for therapeutic prevention.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Hedman, Åsau Pfizer Worldwide Res Dev & Med, External Sci & Innovat, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.4 aut
7001 a Dimitriou, Mariosu Karolinska Institutet,Pfizer Worldwide Res Dev & Med, External Sci & Innovat, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.4 aut
7001 a Desai, Trishnau Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.4 aut
7001 a Sokolov, Aleksandr V.u Uppsala universitet,Funktionell farmakologi och neurovetenskap4 aut0 (Swepub:uu)aleso209
7001 a Schiöth, Helgi B.u Uppsala universitet,Funktionell farmakologi och neurovetenskap4 aut0 (Swepub:uu)helgschi
7001 a Koprulu, Mineu Univ Cambridge, MRC Epidemiol Unit, Cambridge, England.4 aut
7001 a Pietzner, Maiku Univ Cambridge, MRC Epidemiol Unit, Cambridge, England.;Charite Univ Medizin Berlin, Berlin Inst Hlth, Computat Med, Berlin, Germany.;Queen Mary Univ London, Precis Healthcare Inst, London, England.4 aut
7001 a Langenberg, Claudiau Univ Cambridge, MRC Epidemiol Unit, Cambridge, England.;Charite Univ Medizin Berlin, Berlin Inst Hlth, Computat Med, Berlin, Germany.;Queen Mary Univ London, Precis Healthcare Inst, London, England.4 aut
7001 a Atkins, Joshuau Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.4 aut
7001 a Cortez Penha, Ricardou Int Agcy Res Canc IARC WHO, Genom Epidemiol Branch, Lyon, France.4 aut
7001 a McKay, Jamesu Int Agcy Res Canc IARC WHO, Genom Epidemiol Branch, Lyon, France.4 aut
7001 a Brennan, Paulu Int Agcy Res Canc IARC WHO, Genom Epidemiol Branch, Lyon, France.4 aut
7001 a Zhou, Siruiu McGill Univ, Dept Human Genet, Montreal, PQ, Canada.4 aut
7001 a Richards, Brent J.u McGill Univ, Dept Med Endocrinol, Montreal, PQ, Canada.;McGill Univ, Dept Human Genet, Montreal, PQ, Canada.;McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada.4 aut
7001 a Yarmolinsky, Jamesu Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, England.4 aut
7001 a Martin, Richard M.u Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, England.;Univ Bristol, Bristol Med Sch, Populat Hlth Sci, Bristol, England.;Univ Bristol, Hosp Bristol & Weston NHS Fdn Trust, NIHR Bristol Biomed Res Ctr, Bristol, England.4 aut
7001 a Borlido, Joanau Pfizer Inc, Canc Immunol Discovery, Pfizer Worldwide Res & Dev Med, San Diego, CA USA.4 aut
7001 a Mu, Xinmeng J.u Pfizer Inc, Oncol Res Unit, Pfizer Worldwide Res & Dev Med, San Diego, CA USA.4 aut
7001 a Butterworth, Adamu Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England.4 aut
7001 a Shen, Xiau Univ Edinburgh, Usher Inst, MRC Human Genet Unit, Edinburgh, Scotland.4 aut
7001 a Wilson, Jimu Univ Edinburgh, Usher Inst, MRC Human Genet Unit, Edinburgh, Scotland.4 aut
7001 a Assimes, Themistocles L.u Stanford Univ, Div Cardiovasc Med, Stanford, CA USA.;Stanford Univ, Cardiovasc Inst, Sch Med, Stanford, CA USA.4 aut
7001 a Hung, Rayjean J.u Sinai Hlth Syst, Lunenfeld Tanenbaum Res Inst, Prosserman Ctr Hlth Res, Toronto, ON, Canada.;Univ Toronto, Toronto, ON, Canada.4 aut
7001 a Amos, Christopheru Baylor Med Coll, Inst Clin & Translat Res, Dept Med, Epidemiol Sect, Houston, TX USA.4 aut
7001 a Purdue, Marku NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.4 aut
7001 a Rothman, Nathanielu NCI, Div Canc Epidemiol & Genet, Occupat & Environm Epidemiol Branch, Rockville, MD USA.4 aut
7001 a Chanock, Stephenu NCI, Div Canc Epidemiol & Genet, Rockville, MD USA.4 aut
7001 a Travis, Ruth C.u Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.4 aut
7001 a Johansson, Mattiasu Int Agcy Res Canc IARC WHO, Genom Epidemiol Branch, Lyon, France.4 aut
7001 a Mälarstig, Andersu Pfizer Worldwide Res Dev & Med, External Sci & Innovat, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.4 aut
7102 a Univ Oxford, Canc Epidemiol Unit, Oxford Populat Hlth, Oxford, England.b Pfizer Worldwide Res Dev & Med, External Sci & Innovat, Stockholm, Sweden.;Karolinska Inst, Dept Med, Stockholm, Sweden.4 org
7730 t Nature Communicationsd : Springer Natureg 15:1q 15:1x 2041-1723
8564 u https://doi.org/10.1038/s41467-024-46834-3y Fulltext
8564 u https://uu.diva-portal.org/smash/get/diva2:1881908/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-534377
8564 8u https://doi.org/10.1038/s41467-024-46834-3
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:238684708

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy